Dongkook Lifescience Announces 100% Bonus Issue... "Shareholder-Friendly Management Policy"

Record Date for New Share Allocation: August 8
Scheduled Listing Date for New Shares: August 29

Dongkook Lifescience, a company specializing in contrast agents, announced on July 24 that its board of directors has resolved to carry out a 100% bonus issue, allocating one new share for every existing share. As a result, the total number of common shares issued by Dongkook Lifescience is expected to increase from 15,990,000 to 31,980,000.

Dongguk Life Science

According to Dongkook Lifescience, this bonus issue was implemented to strengthen shareholder return policies and to stimulate trading activity by increasing the volume of shares in circulation. The record date for the allocation of new shares is August 8, and the scheduled listing date for the new shares is August 29. Upon completion of the bonus issue, the company's capital will increase from approximately KRW 8 billion to KRW 16 billion.

A Dongkook Lifescience representative stated, "This capital increase was carried out with a focus on maximizing shareholder value and expanding the investor base through increased liquidity," adding, "This is an extension of our shareholder-friendly management policy since our KOSDAQ listing."

With this bonus issue as a turning point, Dongkook Lifescience plans to further accelerate investments in new businesses, including tripling the production capacity of its Anseong plant and developing new MRI contrast agent drugs.

Last year, Dongkook Lifescience recorded cumulative sales of approximately KRW 131.8 billion, a 9.7% increase compared to the previous year, and an operating profit of KRW 11.9 billion, a 39.7% increase. Since its establishment in 2017, the company has achieved an average annual growth rate of 15.6% in sales and 14.5% in operating profit. In particular, strong sales of the contrast agent 'Mediray,' launched in the second half of last year, have continued.

Dongkook Lifescience is the only company in Korea with a vertically integrated system capable of producing everything in-house, from active pharmaceutical ingredients (APIs) to finished pharmaceutical products. Based on this, the company is also actively pursuing new businesses such as the development of new MRI contrast agents and CMO (contract manufacturing organization) services.

This content was produced with the assistance of AI translation services.